CytomX Therapeutics (CTMX) Accumulated Expenses (2014 - 2026)

CytomX Therapeutics has reported Accumulated Expenses for 13 years, with the latest figure at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 2.17% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 2.17% YoY), and the FY2025 full-year result was $14.2 million, up 15.07% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.9 million, down from $14.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $31.7 million in Q2 2022, with the low at $3.8 million in Q1 2025.
• Historically, Accumulated Expenses has averaged $14.4 million across 5 years, with a median of $12.4 million in 2025.
• Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 85.91% — and 2024, when it surged 135.9%.
• CytomX Therapeutics' Accumulated Expenses stood at $8.1 million in 2022, then soared by 118.35% to $17.6 million in 2023, then declined by 29.89% to $12.3 million in 2024, then gained by 15.07% to $14.2 million in 2025, then tumbled by 72.5% to $3.9 million in 2026.
• The last three Accumulated Expenses figures came in at $3.9 million (Q1 2026), $14.2 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.